Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)

被引：5

作者：

Anderson, Alan ^{[1
,2
]}

El Rassi, Fuad ^{[3
]}

DeBaun, Michael R. ^{[4
]}

Idowu, Modupe ^{[5
]}

Kanter, Julie ^{[6
]}

Adam, Soheir ^{[7
]}

Curtis, Susanna ^{[8
]}

Liles, Darla ^{[9
]}

Andemariam, Biree ^{[10
]}

McLemore, Morgan L. ^{[3
]}

Nickel, Robert Sheppard ^{[11
]}

Ramadas, Poornima ^{[12
]}

Paulose, Jincy ^{[13
]}

Laine, Dramane, I ^{[13
]}

Khan, Mahmudul ^{[13
]}

Darbari, Deepika S. ^{[11
]}

Burnett, Arthur L. ^{[14
]}

机构：

[1] Prisma Hlth Upstate Comprehens SCD Program, Greenville, SC USA

[2] Univ South Carolina, Sch Med, Greenville, SC USA

[3] Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA USA

[4] Vanderbilt Univ, Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, Sch Med, Nashville, TN USA

[5] Univ Texas, UT Phys Comprehens Sickle Cell Ctr, Houston, TX USA

[6] Univ Alabama Birmingham, UAB Sickle Cell Clin, Birmingham, AL USA

[7] Duke Univ, Duke Adult Comprehens Sickle Cell Ctr, Durham, NC USA

[8] Albert Einstein Coll Med, Montefiore Med Ctr, New York, NY USA

[9] East Carolina Univ, Brody Sch Med, Greenville, NC USA

[10] Univ Connecticut, New England Sickle Cell Inst, Farmington, CT USA

[11] Childrens Natl Hosp, Comprehens Sickle Cell Dis Program, Washington, DC USA

[12] LSU Hlth Shreveport, Feist Weiller Canc Ctr, Shreveport, LA USA

[13] Novartis Pharmaceut, E Hanover, NJ USA

[14] Johns Hopkins Med Inst, Brady Urol Inst, Baltimore, MD USA

来源：

关键词：

D O I：

10.1182/blood-2022-157004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1636 / 1638

页数：3